These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34569060)

  • 21. Aristolochic acid-associated urothelial cancer in Taiwan.
    Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
    Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
    Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing.
    Zhang Q; Wang C; Qin M; Ye Y; Mo Y; Meng Q; Yang G; Feng G; Lin R; Xian S; Wei J; Chen S; Wang S; Mo Z
    Front Immunol; 2024; 15():1298087. PubMed ID: 38903524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA Profiling in Patients with Upper Tract Urothelial Carcinoma Associated with Balkan Endemic Nephropathy.
    Popovska-Jankovic K; Noveski P; Jankovic-Velickovic L; Stojnev S; Cukuranovic R; Stefanovic V; Toncheva D; Staneva R; Polenakovic M; Plaseska-Karanfilska D
    Biomed Res Int; 2016; 2016():7450461. PubMed ID: 27218105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
    J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
    World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
    Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
    Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
    Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
    Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma.
    Fujii Y; Sato Y; Suzuki H; Kakiuchi N; Yoshizato T; Lenis AT; Maekawa S; Yokoyama A; Takeuchi Y; Inoue Y; Ochi Y; Shiozawa Y; Aoki K; Yoshida K; Kataoka K; Nakagawa MM; Nannya Y; Makishima H; Miyakawa J; Kawai T; Morikawa T; Shiraishi Y; Chiba K; Tanaka H; Nagae G; Sanada M; Sugihara E; Sato TA; Nakagawa T; Fukayama M; Ushiku T; Aburatani H; Miyano S; Coleman JA; Homma Y; Solit DB; Kume H; Ogawa S
    Cancer Cell; 2021 Jun; 39(6):793-809.e8. PubMed ID: 34129823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study.
    Dawood EE; Awadalla A; Hashem A; Shokeir AA; Abdel-Aziz AF
    J Egypt Natl Canc Inst; 2022 Nov; 34(1):47. PubMed ID: 36372809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma.
    Yang K; Yu W; Liu H; Lou F; Cao S; Wang H; He Z
    Cancer Med; 2023 Jul; 12(14):15304-15316. PubMed ID: 37387466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells.
    Bellamri M; Brandt K; Brown CV; Wu MT; Turesky RJ
    Arch Toxicol; 2021 Jun; 95(6):2189-2199. PubMed ID: 33938965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.
    Schmeiser HH; Nortier JL; Singh R; Gamboa da Costa G; Sennesael J; Cassuto-Viguier E; Ambrosetti D; Rorive S; Pozdzik A; Phillips DH; Stiborova M; Arlt VM
    Int J Cancer; 2014 Jul; 135(2):502-7. PubMed ID: 24921086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.
    De Lorenzis E; Albo G; Longo F; Bebi C; Boeri L; Montanari E
    Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33668859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells.
    Chung YH; Li SC; Kao YH; Luo HL; Cheng YT; Lin PR; Tai MH; Chiang PH
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms.
    Han J; Xian Z; Zhang Y; Liu J; Liang A
    Front Pharmacol; 2019; 10():648. PubMed ID: 31244661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center.
    Fang D; Zhang L; Li X; Xiong G; Chen X; Han W; He Z; Zhou L
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):477-85. PubMed ID: 24469253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.